Nov 2, 4:29 PM ET
Inspire Medical Systems reported third-quarter 2026 revenue of $206.7 million, down 7.9% from a year earlier, and a net loss of $24.4 million, or $(0.84) per diluted share, versus earnings of $0.34 per share in the prior-year quarter. The company narrowed its full-year 2026 revenue outlook to $850 million to $860 million and set a GAAP diluted EPS range of $(0.36) to $(0.10), with the loss driven partly by $24.1 million of restructuring charges and $7.0 million of legal settlement expense.
- Q3 2026 revenue of $206.7 million, down from $224.5 million; the company cites U.S. revenue declines tied to coding and reimbursement challenges.
- Diluted EPS of $(0.84) versus $0.34 a year earlier; adjusted diluted EPS of $0.14 versus $0.37.
- Full-year 2026 revenue outlook narrowed to $850 million to $860 million from $835 million to $875 million; adjusted diluted EPS outlook of $1.20 to $1.40.
- Operating cash flow of $46.4 million, compared with $68.5 million in the prior-year quarter.
Read the filing on SEC.gov ↗
Aug 3, 4:03 PM ET
Inspire Medical Systems reported second-quarter 2026 revenue of $200.6 million, down 7.6% from $217.1 million a year earlier, mainly due to a U.S. decline tied to evolving coding and reimbursement, partly offset by International growth. The company swung to a diluted profit of $0.01 per share from a loss of $(0.12), and raised its full-year 2026 revenue outlook to $835 million to $875 million, while announcing Project Horizon, a restructuring plan with $20 million to $25 million of pre-tax charges, mostly non-cash.
- Q2 2026 revenue of $200.6 million versus $217.1 million in Q2 2025; U.S. revenue declined while International revenue grew.
- Diluted EPS of $0.01 versus $(0.12) a year earlier; adjusted diluted EPS of $0.14 versus $0.34.
- Full-year 2026 revenue outlook raised to $835 million to $875 million; adjusted operating margin expected at 4% to 6%.
- Project Horizon restructuring: $20 million to $25 million of pre-tax charges, with about $30 million of annualized growth investment capacity; most actions expected in Q3 and substantially complete by end of 2026.
Read the filing on SEC.gov ↗
Jul 24, 4:01 PM ET
Inspire Medical Systems appointed Michael H. Carrel to its Board of Directors effective immediately on July 20, 2026, as a Class III director with a term expiring at the 2027 Annual Meeting. Mr. Carrel is president, chief executive officer and a director of AtriCure, Inc., and he was also named to the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee.
- Board appointment effective immediately, made July 20, 2026, on the recommendation of the Nominating and Corporate Governance Committee
- Mr. Carrel has been CEO of AtriCure, Inc. (NASDAQ: ATRC) since November 2012
- Director compensation includes a $55,000 annual cash retainer, a $300,000 initial restricted stock unit award vesting over three years, and a $200,000 annual restricted stock unit award
- Committee retainers of $7,500 each apply for the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee
Read the filing on SEC.gov ↗
Jul 22, 8:02 AM ET
Inspire Medical Systems said director Casey Tansey, a board member for more than eighteen years, will retire from the board effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting. The company said the decision was not the result of any disagreement with the company or any matter relating to its operations, policies or practices, and it expects to name a replacement director in the near future.
- Casey Tansey's retirement from the board and its committees is effective July 30, 2026.
- Tansey led the Series A financing in November 2007 for U.S. Venture Partners and has served on the board since then.
- The company said it expects to announce a new director to replace Tansey in the near future.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.